Addrenex submits a sNDA to the FDA for Clonicel Sciele Pharma, Inc., a Shionogi firm, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application to america Food and Drug Administration for Clonicel to take care of interest deficit hyperactivity disorder . In multi-center, placebo-controlled, double-blind, randomized Stage III clinical trials, Clonicel demonstrated statistical significance when used to treat ADHD. Related StoriesNovo Nordisk announces FDA acceptance of Tresiba for diabetes treatmentAllergan settles patent litigation with Amneal related to NAMENDA XR extended launch capsulesMylan announces U.S.BHO actually leeches the Tetrahydrocannabinol from the marijuana plant and it pours out in a greenish mess into the pan. Though, marijuana wax could be manufactured in the house only with all the necessary equipment nonetheless it is preferred from many experts not to try to produce the marijuana wax in case you are not really sure about it.
Ala. Lawmakers approve controversial brand-new abortion clinic regulations The measure, which still should be signed by the governor, would help to make abortion clinics use doctors with admitting privileges at local hospitals, a move opponents say could force the state's five clinics to close.